Article summary
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational New Drug (Pre-IND) meeting by the U.S. Food and Drug Administration (FDA) for new chemical entity Triptaxβ’. Biomind Labs is devoted to crafting innovative pharmaceuticals for patients with neurological and psychiatric disorders, using cutting-edge science to harness the powerful medicinal qualities of psychedelics. The company specializes in research and development transformation of biomedical sciences knowledge into pharmaceutical drugs and nanotech delivery systems for treating psychiatric and neurological conditions. What is a New Chemical Entity? A new chemical entity, The post Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax appeared first on Psychedelic Chronicle.
Continue to the original publication for the complete article.